Skip to content
Terminus Peptides
  • Research use only — not for human or veterinary use
  • 55 compound profiles, every source cited
  • 62 research materials listed
  • Prices published, not hidden behind an enquiry
  • Vials and pre-filled pens
  • Dispatched and supported from the UK
  • Every profile states its UK regulatory status

Research profile · Peptide analogue

CJC-1295 with DAC

Also known as CJC-1295 DAC, Modified GRF with drug affinity complex

Early human — evidence level 3 of 4: Early human evidenceExperimental — UK regulatory status: Experimental — not authorised for human use in the UK

Overview

A growth hormone-releasing hormone analogue carrying an albumin-binding moiety that extends its half-life to several days.

Category
Peptide analogue
Highest evidence level identified
Early human evidence
Last scientifically reviewed
20 August 2026
Last regulatory review
20 August 2026

Mechanism under investigation

CJC-1295 is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone, modified to resist enzymatic degradation, and proposed to act as an agonist at the pituitary receptor for that hormone. The form carrying a drug affinity complex additionally binds covalently to serum albumin, which extends the measured half-life to roughly six to eight days. That extended exposure is the compound’s defining property and also the principal source of uncertainty about it.

Research areas

  • Pituitary endocrinology

These are fields in which the compound has been investigated. Listing a field is not a statement that anything was demonstrated within it.

Current evidence

In-vitro evidence

Cells, tissues or biochemical systems outside a living organism.

Sparse in the public literature. The design rationale rests on degradation-resistance chemistry rather than on published independent receptor pharmacology.

Animal evidence

Studies in living non-human animals.

Sparse. No substantial published animal efficacy programme was located; the compound advanced quickly to human phase 1 under its original developer.

Human observational evidence

Studies observing people without assigning an intervention.

Absent. No cohort, registry or case-control data exist. The compound appears in human-facing literature chiefly through anti-doping detection method development and forensic analysis of seized material.

Clinical-trial evidence

Studies assigning an intervention to human participants.

Two published phase 1 pharmacokinetic studies in healthy adults, both from 2006, reporting dose-dependent growth hormone increases and IGF-1 elevation persisting for weeks after repeated administration, with pulsatile secretion preserved. There are no controlled efficacy trials and no phase 2 or 3 data for any clinical indication, and the phase 1 work has not been independently replicated in twenty years.

Study limitations

  • The entire human evidence base is two small phase 1 studies in healthy volunteers from 2006, measuring hormone concentrations rather than clinical outcomes, with no independent replication since.
  • Raising growth hormone and IGF-1 is a biomarker result, not a demonstrated benefit. No trial has tested whether it produces any change in body composition, function or wellbeing.
  • Sustained elevation of IGF-1 for weeks after dosing is the compound’s stated pharmacological aim and also the principal theoretical concern, and it has not been studied over a duration that would resolve that either way.
  • The phase 1 studies were far too small and brief to detect uncommon harms.

UK regulatory context

Experimental — not authorised for human use in the UK

A compound appearing in research literature that holds no UK authorisation for human use in any indication.

Source: The Human Medicines Regulations 2012, regulation 46 — prohibition on sale or supply of an unauthorised medicinal product (opens legislation.gov.uk in a new tab) (legislation.gov.uk)

Regulatory classification is jurisdiction-specific. A compound authorised elsewhere is not thereby authorised in the UK, and a supplier’s description of a substance does not determine how it is classified in law. See safety and regulation for the framework and the authoritative sources.

Safety and interpretation

The phase 1 studies described the compound as generally tolerated over short observation windows, but they were small, brief and conducted in healthy volunteers, so they cannot characterise the risks of repeated or prolonged use. The prolonged IGF-1 elevation that the compound is designed to produce has not been studied over any meaningful duration.

References